Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology
23 mai 2023 08h30 HE
|
Sight Sciences, Inc.
Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 monthsSustained and...
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
06 mai 2023 11h30 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that enables...
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
04 mai 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions...
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
01 mai 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
26 avr. 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
20 avr. 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
13 avr. 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative...
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
03 avr. 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions...
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
30 mars 2023 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative...
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
13 mars 2023 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative...